ALBO stock forecast
Our latest prediction for Albireo Pharma Inc's stock price was made on the Jan. 20, 2023 when the stock price was at 43.81$.
In the short term (2weeks), ALBO's stock price should underperform the market by -4.00%. During that period the price should oscillate between -12.49% and +7.76%.
In the medium term (3months), ALBO's stock price should underperform the market by -19.55%. During that period the price should oscillate between -29.21% and +14.56%.
Get email alertsCreate a solid portfolio with ALBO
About Albireo Pharma Inc
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
At the moment the company generates 13M USD in revenues.
On its last earning announcement, the company reported a loss of -6.72$ per share.
The book value per share is 12.49$
Three months stock forecastJan. 20, 2023
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13M | 20.02% | -122M | -906.09% | 8M | -6.72 | - | - | 20M | 12.49 | - | - | - |